Evidence map›Paper›PMID 38234835›Full record

ArticlebioRxiv : the preprint server for biology2023

CRISPRmap: Sequencing-free optical pooled screens mapping multi-omic phenotypes in cells and tissue.

Jiacheng Gu, Abhishek Iyer, Ben Wesley, Angelo Taglialatela, Giuseppe Leuzzi, Sho Hangai, Aubrianna Decker, Ruoyu Gu, Naomi Klickstein, Yuanlong Shuai and 12 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 10 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 3 institutions in 1 country.

Jiacheng GuDepartment of Biological Sciences, Columbia University, NY, USA.
Abhishek IyerDepartment of Biological Sciences, Columbia University, NY, USA.
Ben WesleyDepartment of Biological Sciences, Columbia University, NY, USA.
Angelo TaglialatelaDepartment of Genetics and Development, Columbia University Irving Medical Center, NY, USA.
Giuseppe LeuzziDepartment of Genetics and Development, Columbia University Irving Medical Center, NY, USA.
Sho HangaiHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, NY, USA.
Aubrianna DeckerDepartment of Biological Sciences, Columbia University, NY, USA.
Ruoyu GuDepartment of Biological Sciences, Columbia University, NY, USA.
Naomi KlicksteinDepartment of Biological Sciences, Columbia University, NY, USA.
Yuanlong ShuaiDepartment of Biological Sciences, Columbia University, NY, USA.
Kristina JankovicHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, NY, USA.
Lucy Parker-BurnsHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, NY, USA.
Yinuo JinDepartment of Biomedical Engineering, Columbia University, NY, USA.
Jia Yi ZhangDepartment of Biomedical Engineering, Columbia University, NY, USA.
Justin HongDepartment of Computer Science, Columbia University, NY, USA.
Steve NiuWeill Cornell Medicine, NY, USA.
Jacqueline ChouDepartment of Biological Sciences, Columbia University, NY, USA.
Dan A LandauWeill Cornell Medicine, NY, USA.
Elham AziziDepartment of Biomedical Engineering, Columbia University, NY, USA.
Edmond M ChanHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, NY, USA.
Alberto CicciaDepartment of Genetics and Development, Columbia University Irving Medical Center, NY, USA.
Jellert T GaublommeDepartment of Biological Sciences, Columbia University, NY, USA.ORCID 0000-0002-1266-052X
Columbia University · USColumbia University Irving Medical Center · USCornell University · US

Funding

Replication fork remodeling and genomic stabilityR01CA197774 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Alberto Ciccia · 2016 to 2026
$4.2M
SPATIALLY MAPPING OF POOLED IN VIVO CRISPR SCREENS IN THE TUMOR MICROENVIRONMENTDP2CA281605 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI GAUBLOMME, JELLERT · 2022 to 2025
$2.5M
Restoring genome stability and tumor suppression in BRCA1 deficient cellsR01CA227450 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BAER, RICHARD J, CICCIA, ALBERTO · 2019 to 2022
$2.1M
Machine learning methods for interpreting spatial multi-omics dataR01HG012875 · NHGRI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Elham Azizi · 2023 to 2026
$1.7M
Computational toolbox for spatial transcriptomic analysis of complex tissuesR21HG012639 · NHGRI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI AZIZI, ELHAM · 2023 to 2023
$435k
NCI NIH HHS DP2 CA281605NCI NIH HHS R01 CA197774NCI NIH HHS R01 CA227450NHGRI NIH HHS R01 HG012875NHGRI NIH HHS R21 HG012639
6 · The paper itself

Abstract

Pooled genetic screens are powerful tools to study gene function in a high-throughput manner. Typically, sequencing-based screens require cell lysis, which limits the examination of critical phenotypes such as cell morphology, protein subcellular localization, and cell-cell/tissue interactions. In contrast, emerging optical pooled screening methods enable the investigation of these spatial phenotypes in response to targeted CRISPR perturbations. In this study, we report a multi-omic optical pooled CRISPR screening method, which we have named CRISPRmap. Our method combines a novel in situ CRISPR guide identifying barcode readout approach with concurrent multiplexed immunofluorescence and in situ RNA detection. CRISPRmap barcodes are detected and read out through combinatorial hybridization of DNA oligos, enhancing barcode detection efficiency, while reducing both dependency on third party proprietary sequencing reagents and assay cost. Notably, we conducted a multi-omic base-editing screen in a breast cancer cell line on core DNA damage repair genes involved in the homologous recombination and Fanconi anemia pathways investigating how nucleotide variants in those genes influence DNA damage signaling and cell cycle regulation following treatment with ionizing radiation or DNA damaging agents commonly used for cancer therapy. Approximately a million cells were profiled with our multi-omic approach, providing a comprehensive phenotypic assessment of the functional consequences of the studied variants. CRISPRmap enabled us to pinpoint likely-pathogenic patient-derived mutations that were previously classified as variants of unknown clinical significance. Furthermore, our approach effectively distinguished barcodes of a pooled library in tumor tissue, and we coupled it with cell-type and molecular phenotyping by cyclic immunofluorescence. Multi-omic spatial analysis of how CRISPR-perturbed cells respond to various environmental cues in the tissue context offers the potential to significantly expand our understanding of tissue biology in both health and disease.

Identifiers

PMID38234835
PMCPMC10793456
OpenAlexW4390244727

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.